0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Contribution |

Relation of Diabetes to Mild Cognitive Impairment FREE

José A. Luchsinger, MD; Christiane Reitz, MD; Bindu Patel, MPH; Ming-Xin Tang, PhD; Jennifer J. Manly, PhD; Richard Mayeux, MD
[+] Author Affiliations

Author Affiliations: Taub Institute for Research of Alzheimer's Disease and the Aging Brain (Drs Luchsinger, Tang, Manly, and Mayeux and Ms Patel), Gertrude H. Sergievsky Center (Drs Luchsinger, Reitz, Manly, and Mayeux), and Departments of Biostatistics (Dr Tang) and Epidemiology (Drs Luchsinger and Mayeux), Joseph P. Mailman School of Public Health; and Departments of Medicine (Dr Luchsinger), Neurology (Drs Manly and Mayeux), and Psychiatry (Dr Mayeux), College of Physicians and Surgeons, Columbia University, New York, NY.


Arch Neurol. 2007;64(4):570-575. doi:10.1001/archneur.64.4.570.
Text Size: A A A
Published online

Background  Type 2 diabetes mellitus is an important risk factor for Alzheimer disease and is more prevalent in elderly minority persons compared with non-Hispanic white persons.

Objective  To determine whether diabetes is related to a higher risk of mild cognitive impairment (MCI), a transitional stage between normal cognition and Alzheimer disease, in a multiethnic cohort with a high prevalence of diabetes.

Design  Longitudinal cohort study.

Setting  Northern Manhattan in New York, NY.

Participants  We studied persons without prevalent MCI or dementia at baseline and with at least 1 follow-up interval. Of 1772 participants with a complete neuropsychological evaluation, 339 (19.1%) were excluded because of prevalent dementia, 304 were excluded because of prevalent MCI (17.2%), and 211 were excluded because of loss to follow-up (11.9%), resulting in a final sample of 918 participants for longitudinal analyses.

Main Outcome Measures  We related diabetes defined by self-report to incident all-cause MCI, amnestic MCI, and nonamnestic MCI. We conducted multivariate analyses with proportional hazards regression adjusting for age, sex, years of education, ethnic group, apolipoprotein E (APOE) ε4 allele, hypertension, low-density lipoprotein level, current smoking, heart disease, and stroke.

Results  A total of 334 persons had incident MCI, 160 (47.9%) had amnestic MCI, and 174 (52.1%) had nonamnestic MCI. Diabetes was related to a significantly higher risk of all-cause MCI and amnestic MCI after adjustment for all covariates. Diabetes was also related to a higher risk of nonamnestic MCI, but this association was appreciably attenuated after adjustment for socioeconomic variables and vascular risk factors. The risk of MCI attributable to diabetes was 8.8% for the whole sample and was higher for African American persons (8.4%) and Hispanic persons (11.0%) compared with non-Hispanic white persons (4.6%), reflecting the higher prevalence of diabetes in minority populations in the United States.

Conclusion  Diabetes is related to a higher risk of amnestic MCI in a population with a high prevalence of this disorder.

Among cardiovascular risk factors, type 2 diabetes mellitus has been consistently related to a higher risk of Alzheimer disease (AD).16 This association is presumed to be the result of the effects of peripheral hyperinsulinemia on the clearance of brain amyloid β,7,8 the putative main culprit in the pathogenesis of AD,9 or of other mechanisms such as advanced products of glycosylation.10 The prevalence of diabetes is more than 10% in the elderly population in the United States,11 is twice as high in African American and Hispanic populations compared with non-Hispanic white populations,12 and is more than 20% in persons 65 years or older in the predominantly minority population of northern Manhattan in New York, NY.13

Interest is growing in preclinical transitional states of AD as targets for treatment and prevention. Mild cognitive impairment (MCI), and particularly amnestic MCI, has been described as a transitional state between normal cognition and AD1416 that is increasingly used in clinical and research settings. We previously demonstrated that diabetes is associated with an increased risk of AD and dementia.2,17 Thus, we hypothesized that diabetes is also related to a higher risk of MCI, particularly amnestic MCI.

PARTICIPANTS AND SETTING

Participants were from a longitudinal cohort study of Medicare recipients 65 years or older residing in northern Manhattan (Washington Heights, Hamilton Heights, and Inwood).18 Each participant underwent an in-person interview of general health and function at the time of study entry followed by a standard assessment, including medical history, physical and neurological examination, and a neuropsychological battery.19 These assessments were performed at each follow-up interval. Baseline data were collected from 1992 through 1994 and follow-up data every 18 months until 2003. The institutional review board of Columbia-Presbyterian Medical Center (New York, NY) approved this study.

Our study included persons without prevalent MCI or dementia at baseline and with at least 1 follow-up interval. Of 1772 participants with a complete neuropsychological evaluation, 339 (19.1%) were excluded because of prevalent dementia, 304 because of prevalent MCI (17.2%), and 211 because of loss to follow-up (11.9%), resulting in a final sample of 918 participants for longitudinal analyses. Compared with the original 1772 participants, the final sample without prevalent MCI and dementia and with prospective data was younger (mean ± SD age, 75.9 ± 6.0 vs 77.3 ± 6.8 years; P<.001), had a similar distribution of women (69.4% vs 69.4%) and African American participants (33.6% vs 32.3%), had a lower proportion of Hispanic participants (43.9% vs 47.0%; P<.001), had a higher proportion of non-Hispanic white participants (22.6% vs 20.4%; P = .008), and had a lower prevalence of diabetes (23.9% vs 26.4%; P = .004).

NEUROPSYCHOLOGICAL BATTERY

The neuropsychological measures used in this study have been previously described.19 The evaluation included measures of learning and memory, orientation, abstract reasoning, language, and visuospatial ability. Specific ability areas and tests administered included verbal list learning and memory (Selective Reminding Test20), nonverbal memory (multiple-choice version of the Benton Visual Retention Test21), orientation (items from the Mini-Mental State Examination22), verbal reasoning (similarities subtest of the Wechsler Adult Intelligence Scale–Revised23), nonverbal reasoning (identities and oddities subtest of the Mattis Dementia Rating Scale24), naming (15-item version of the Boston Naming Test25), letter fluency (Controlled Word Association26), category fluency (animals, food, and clothing, using procedures from the Boston Diagnostic Aphasia Examination [BDAE]27), repetition (high-frequency phrases of the BDAE27), auditory comprehension (first 6 items of the complex ideational material subtest of the BDAE28), visuoconstruction (Rosen Drawing Test29), and visuoperceptual skills (multiple-choice matching of figures from the Benton Visual Retention Test21). Norms for these tests to diagnose MCI have been previously described.30

DIAGNOSIS OF DEMENTIA

Diagnosis of dementia and assignment of specific cause were made by consensus of 2 neurologists, 1 psychiatrist, and 2 neuropsychologists based on baseline and follow-up information. The diagnosis of dementia was based on Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) criteria31 and required evidence of cognitive deficits on the neuropsychological test battery as well as evidence of impairment in social or occupational function (Clinical Dementia Rating of 1 or more).32 Diagnosis of AD was based on the National Institute of Neurological Disorders and Stroke–Alzheimer's Disease and Related Disorder Association criteria.33

MCI DIAGNOSTIC CRITERIA

The MCI criteria were retrospectively applied among persons without dementia. Consistent with standard criteria,16 for all subtypes of MCI, those considered for MCI were required to have the following: (1) memory complaints; (2) objective impairment in at least 1 cognitive domain based on the average of the scores on the neuropsychological measures within that domain and a 1.5-SD cutoff using normative corrections for age, years of education, ethnicity, and sex; (3) essentially preserved activities of daily living; and (4) no diagnosis of dementia at the consensus conference.

To cast the widest net to determine prevalence of MCI and to determine which individuals were more likely to progress to dementia, we expanded the original Petersen criteria,34 which focus on memory impairment, to include mutually exclusive subtypes based on cognitive features. Our first subtype, amnestic MCI, corresponds most closely to the original definition used by Petersen and colleagues. Memory impairment was defined as a score of less than 1.5 SDs below the demographically corrected mean on an average composite measure that comprised the following learning and memory measures: (1) total recall from the Selective Reminding Test, (2) delayed free recall from the Selective Reminding Test, and (3) recognition from the Benton Visual Retention Test. Performance on composite scores from all other cognitive domains (ie, executive, language, and visuospatial) was required to be within normal limits (score must be ≥1.5 SDs below the demographically corrected mean). Other MCI subtypes were classified that allowed for impairment in a single nonmemory domain if performance on composite scores from all other cognitive domains was within normal limits. Executive MCI was assigned if impairment was demonstrated on an average composite measure that comprised the following measures: (1) letter fluency, (2) category fluency, and (3) the Wechsler Adult Intelligence Scale–Revised similarities subtest. Language MCI was defined as isolated impairment on an average composite measure that comprised (1) the Boston Naming Test, (2) the BDAE repetition test, and (3) the BDAE comprehension test. Visuospatial MCI was assigned if impairment was demonstrated on an average composite measure that comprised (1) Rosen Drawing and (2) Benton Visual Retention Test matching. Finally, we allowed for impairment in multiple cognitive domains in the absence of dementia. Multiple cognitive domains with memory impairment MCI (MCI-MCDM) was diagnosed if there was objective impairment on the memory domain composite score and if there was impairment on at least 1 other cognitive domain. Multiple cognitive domains without memory impairment MCI was assigned if there was impairment in 2 or more of the 3 nonmemory domains and if the memory domain composite score was within normal limits. Classification into the 6 subtypes was mutually exclusive. We used 3 outcomes for these analyses: (1) all-cause MCI; (2) amnestic MCI, which included amnestic MCI and MCI-MCDM; and (3) nonamnestic MCI. The rationale for grouping amnestic MCI and MCI-MCDM is that amnestic MCI and MCI-MCDM equally predict the development of AD and MCI-MCDM is thought to be a more advanced form of amnestic MCI involving other cognitive domains.

DEFINITION OF DIABETES AND OTHER COVARIATES

History of type 2 diabetes mellitus was ascertained by self-report or the use of diabetes medications at baseline and each follow-up visit. Hypertension, heart disease, and smoking were defined by self-report. Heart disease included a history of atrial fibrillation and other arrhythmias, congestive heart failure, myocardial infarction, and angina pectoris. Smoking was classified into never, current, and past smoking. Fasting plasma total cholesterol and triglyceride levels were determined at the first follow-up using standard enzymatic techniques. High-density lipoprotein cholesterol levels were determined after precipitation of apolipoprotein B–containing lipoproteins with phosphotungstic acid.35 The low-density lipoprotein cholesterol level was recalculated using the formula of Friedewald et al.36 The apolipoprotein E (APOE) genotypes were determined as described by Hixson and Vernier37 with slight modification.38 We classified persons as homozygous or heterozygous for the APOE ε4 allele or as not having any ε4 allele.

STATISTICAL ANALYSIS

Bivariate analyses compared variables between persons with and without diabetes. Continuous variables were compared using analysis of variance, and categorical variables were compared using χ2 tests.39 Cox proportional hazards regression models40 were used in multivariate analyses exploring the association of diabetes with incident all-cause MCI, amnestic MCI, and nonamnestic MCI. The time-to-event variable was age at diagnosis of MCI. Among individuals who did not develop MCI, those who developed dementia were censored at the time of dementia diagnosis, and those who did not develop dementia were censored at the time of last follow-up. We show the results of multivariate analyses for 3 models: 1 adjusted for age and sex; 1 adjusted also for education, ethnic group, and APOE ε4; and 1 additionally adjusted for hypertension, low-density lipoprotein cholesterol level, heart disease, stroke, and current smoking, with the caveat that some of these variables may be in the causal pathway between diabetes and cognitive disorders,17 and attenuation of the hazard ratios (HRs) in this model should be considered evidence of mediation and not of confounding. The risk of MCI attributable to diabetes was calculated using the following formula:

PAR = p(RR − 1)/[1 + p(RR − 1)],

where PAR is population attributable risk, RR is the adjusted HR obtained from the multivariate models, and p is the prevalence of diabetes in this sample.41 All analyses were conducted using SAS statistical software, version 9.1 for Windows (SAS Institute Inc, Cary, NC).

There were 334 incident MCI cases, 160 amnestic MCI cases and 174 cases of nonamnestic MCI in 5556 person-years of follow-up (mean ± SD, 6.1 ± 3.2 years per person). The mean ± SD age of the sample was 75.9 ± 6.0 years, and the mean ± SD duration of education was 8.9 ± 4.6 years. Women represented 69.9% of the sample, 43.9% were Hispanic, 33.6% were African American, and 22.5% were non-Hispanic white. Diabetes was reported by 23.9% of persons, hypertension by 68.2%, heart disease by 33.9%, and stroke by 15.0%; 28.3% of the sample carried the APOE ε4 allele. The mean ± SD low-density lipoprotein cholesterol level was 120.4 ± 36.7 mg/dL (3.12 ± 0.95 mmol/L).

Compared with persons without diabetes, persons with diabetes were younger, were more likely to be Hispanic, were less likely to be non-Hispanic white, had fewer years of education, and were more likely to have hypertension, heart disease, and stroke (Table 1). Persons with incident MCI were more likely to report diabetes and hypertension at baseline and had a longer study follow-up time (Table 2).

Table Graphic Jump LocationTable 1. Demographic and Other Relevant Characteristics of Persons With and Without Diabetes: The Washington Heights–Inwood Columbia Aging Project, 1992-2003*
Table Graphic Jump LocationTable 2. Relevant Characteristics Among Persons Without and With MCI, Amnestic MCI, and Nonamnestic MCI: The Washington Heights–Inwood Columbia Aging Project, 1992-2003*

In multivariate analyses (Table 3), diabetes was related to a higher risk of all-cause MCI even after adjusting for age, sex, ethnic group, years of education, APOE ε4, hypertension, low-density lipoprotein level, heart disease, stroke, and current smoking (HR, 1.4; 95% confidence interval [CI], 1.1-1.8).

Table Graphic Jump LocationTable 3. HRs and 95% CIs Relating Diabetes to MCI, Amnestic MCI, and Nonamnestic MCI*

When only amnestic MCI was considered the outcome of interest, the HR was unchanged (HR, 1.5; 95% CI, 1.0-2.2). When nonamnestic MCI was considered, diabetes was related to a higher risk in the model adjusted for age and sex (HR, 1.4; 95% CI, 1.0-1.9), but it became nonsignificant after adjusting for ethnic group, years of education, and APOE ε4 (HR, 1.3; 95% CI, 0.9-1.8). The HR attenuated further after adjusting for other vascular risk factors, heart disease, and stroke (HR, 1.2; 95% CI, 0.9-1.8).

The association between diabetes and MCI was not modified by the presence of APOE ε4. Compared with persons without diabetes and without APOE ε4, persons with diabetes and the APOE ε4 allele had an HR of 1.3 (95% CI, 0.8-2.1), whereas persons with diabetes without the APOE ε4 allele had an HR of 1.5 (95% CI, 1.1-1.9) in the full model. No effect modification by age (categorized by the median) or sex was found.

We calculated the risk of MCI attributable to diabetes for the whole sample and for each ethnic group. The prevalence of diabetes was 23.1% in African American persons, 30.8% in Hispanic persons, and 11.6% in non-Hispanic white persons, comparable to data from national surveys.12 The risk of MCI attributable to diabetes was 8.8% for the whole sample, 8.4% for African American persons, 11.0% for Hispanic persons, and 4.6% for non-Hispanic white persons, reflecting the differences in diabetes prevalence by ethnic group.

Diabetes was associated with a higher risk of incident all-cause MCI in a population with a high prevalence of this disorder. It was also related to a higher risk of amnestic MCI after adjustment for vascular risk factors, heart disease, and stroke, but the relation to nonamnestic MCI was attenuated after adjustment for these covariates.

Amnestic MCI has been described as a transitional stage between normal cognition and AD.1416 Nonamnestic MCI may be related to cerebrovascular disease or other cognitive disorders and does not predict the onset of AD.42 Diabetes is related to a higher risk of AD.13,5 Thus, we expected that it would be related to all-cause and amnestic MCI, which is a predictor of AD. Because diabetes is related to a higher risk of cerebrovascular disease and vascular dementia,43,44 we also expected that it would be related to a higher risk of nonamnestic MCI, which is more likely to be related to vascular cognitive syndromes.42 Diabetes could be related to a higher risk of AD and amnestic MCI through direct mechanisms, affecting the amyloid accumulation that is the putative culprit of AD,9 or indirect mechanisms, namely cerebrovascular disease,17 which is also related to a higher risk of AD.4547 Hyperinsulinemia, which can precede and accompany diabetes,48 may disrupt brain amyloid β clearance by means of the insulin degrading enzyme.7 Another potential mechanism is the generation of advanced products of glycosylation.10,49,50 In our analyses, diabetes was related to a higher risk of amnestic MCI even after adjusting for stroke and vascular risk factors, which suggests that the association between diabetes and amnestic MCI is independent of cerebrovascular disease (assuming that potential residual confounding was not significant enough to account for the association). Conversely, the relation of diabetes to nonamnestic MCI was appreciably attenuated and became nonsignificant after adjustment for stroke and vascular risk factors, suggesting that cerebrovascular disease may mediate the relation between diabetes and nonamnestic MCI.

Our findings have alternative explanations. Diabetes is more prevalent in African American, Hispanic, and lower socioeconomic groups.12 The risk of AD is also higher in African American and Hispanic populations51 and in persons with lower educational level52; thus, confounding by ethnic group and socioeconomic status could contribute to our results. We adjusted for ethnic group and years of education without an appreciable change in our results for amnestic MCI. Bias related to the selection of an older cohort of community-dwelling survivors is also possible. Finally, it is possible that our results are explained by chance. However, our findings are consistent with published work relating diabetes to AD in the context of biologically plausible mechanisms.

The prevalence of diabetes was appreciably higher in our study compared with others that have examined the association between diabetes and cognitive impairment, which may raise the issue of sampling bias. However, the high prevalence of diabetes in our study is explained by the fact that it is twice as high in African American and Hispanic elderly persons,12,53 who constituted 77.5% of our sample. The prevalence of self-reported diabetes has increased at a 3-fold faster rate in minority compared with white populations.54 Thus, the high prevalence of diabetes in our sample would be expected in the elderly population of New York City and is in line with national estimates from the national surveys. However, most data on Hispanic populations from national surveys pertain to Mexican Hispanic populations. Virtually all of our Hispanic population is Caribbean Hispanic, mostly from the Dominican Republic, and our study is one of the few sources of information on diabetes prevalence in this population. One of the consequences of the higher prevalence of diabetes in African American and Hispanic people is that the risk of MCI attributable to diabetes in these groups is approximately twice that of non-Hispanic white populations, underscoring the importance of diabetes as a risk factor for MCI particularly in African American and Hispanic elderly populations.

The main limitation of our study is the ascertainment of diabetes by self-report. We did not have measures of glycemia and could not ascertain undiagnosed diabetes or glucose intolerance. Had we defined diabetes by self-report and fasting glycemia, our estimates of the prevalence of diabetes would have been higher than we report. Thus, it is likely that our results are biased toward the null hypothesis and that our findings underestimate the true association between diabetes and MCI.

Our results provide further support to the potentially important independent role of diabetes in the pathogenesis of AD. Diabetes may also be a risk factor for nonamnestic forms of MCI and cognitive impairment, but our analyses need to be repeated in a larger sample.

Correspondence: José A. Luchsinger, MD, Department of Medicine, Columbia University, 630 W 168th St, PH9E-105, New York, NY 10032 (jal94@columbia.edu).

Accepted for Publication: April 24, 2006.

Author Contributions:Study concept and design: Luchsinger. Acquisition of data: Luchsinger, Manly, and Mayeux. Analysis and interpretation of data: Luchsinger, Reitz, Patel, and Tang. Drafting of the manuscript: Luchsinger, Reitz, Patel, and Tang. Critical revision of the manuscript for important intellectual content: Luchsinger, Manly, and Mayeux. Statistical analysis: Luchsinger and Tang. Obtained funding: Luchsinger, Manly, and Mayeux. Administrative, technical, and material support: Mayeux.

Financial Disclosure: None reported.

Funding/Support: Support for this work was provided by National Institutes of Health grants AG07232, AG07702, 1K08AG20856-01, and RR00645, the Charles S. Robertson Memorial Gift for Research on Alzheimer's Disease, the Blanchette Hooker Rockefeller Foundation, and the New York City Council Speaker's Fund for Public Health Research.

Peila  RRodriguez  BLLauner  LJ Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002;511256- 1262
PubMed Link to Article
Luchsinger  JATang  MXStern  YShea  SMayeux  R Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154635- 641
PubMed Link to Article
Ott  AStolk  RPvan Harskamp  FPols  HAHofman  ABreteler  MM Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999;531937- 1942
PubMed Link to Article
Ott  AStolk  RPHofman  Avan Harskamp  FGrobbee  DEBreteler  MM Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996;391392- 1397
PubMed Link to Article
Leibson  CLRocca  WAHanson  VA  et al.  Risk of dementia among persons with diabetes mellitus: a population- based cohort study. Am J Epidemiol 1997;145301- 308
PubMed Link to Article
Luchsinger  JATang  MXShea  SMayeux  R Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;631187- 1192
PubMed Link to Article
Farris  WMansourian  SChang  Y  et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003;1004162- 4167
PubMed Link to Article
Qiu  WQWalsh  DMYe  Z  et al.  Insulin-degrading enzyme regulates extracellular levels of amyloid beta- protein by degradation. J Biol Chem 1998;27332730- 32738
PubMed Link to Article
Selkoe  DJ The origins of Alzheimer disease: a is for amyloid. JAMA 2000;2831615- 1617
PubMed Link to Article
Smith  MASayre  LMPerry  G Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link. Diabetologia 1996;39247
PubMed Link to Article
Harris  MI Diabetes in America: epidemiology and scope of the problem. Diabetes Care 1998;21(suppl 3)C11- C14
PubMed
Luchsinger  JA Diabetes. In: Aguirre-Molina  M, Molina  CW, Zambrana  RE, eds.Health Issues in the Latino Community. San Francisco, Calif: Jossey-Bass; 2001:277-300
Luchsinger  JAReitz  CHonig  LSTang  MXShea  SMayeux  R Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005;65545- 551
PubMed Link to Article
Petersen  RC Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologia 1995;1326- 344
Petersen  RC Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256183- 194
PubMed Link to Article
Petersen  RCDoody  RKurz  A  et al.  Current concepts in mild cognitive impairment. Arch Neurol 2001;581985- 1992
PubMed Link to Article
Luchsinger  JAMayeux  R Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004;6261- 266
PubMed Link to Article
Tang  MXStern  YMarder  K  et al.  The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279751- 755
PubMed Link to Article
Stern  YAndrews  HPittman  J  et al.  Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49453- 460
PubMed Link to Article
Buschke  HFuld  PA Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974;241019- 1025
PubMed Link to Article
Benton  AL The Benton Visual Retention Test.  New York, NY: Psychological Corp; 1955
Folstein  MFFolstein  SEMcHugh  PR “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12189- 198
PubMed Link to Article
Weschler  D Wechsler Memory Scale-Revised Manual.  New York, NY: Psychological Corp; 1987
Mattis  S Mental Status Examination for Organic Mental Syndrome in the Elderly Patient.  New York, NY: Grune & Stratton; 1976
Kaplan  EGoodglass  HWeintraub  S Boston Naming Test.  Philadelphia, Pa: Lea & Febiger; 1983
Benton  ALHamsher  KD Multilingual Aphasia Examination.  Iowa City: University of Iowa; 1976
Goodglass  HKaplan  E Assessment of Aphasia and Related Disorders.  Philadelphia, Pa: Lea & Febiger; 1983
Goodglass  HKaplan  E The Assessment of Aphasia and Related Disorders.  Philadelphia, Pa: Lea & Febiger; 1972
Rosen  W The Rosen Drawing Test.  Bronx, NY: Veterans Administration Medical Center; 1981
Manly  JJBell-McGinty  STang  M-XSchupf  NStern  YMayeux  R Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol 2005;621739- 1746
PubMed Link to Article
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994
Hughes  CPBerg  LDanziger  WLCoben  LAMartin  RL A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140566- 572
PubMed Link to Article
McKhann  GDrachman  DFolstein  MKatzman  RPrice  DStadlan  EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34939- 944
PubMed Link to Article
Petersen  RCStevens  JCGanguli  MTangalos  EGCummings  JLDeKosky  ST Early detection of dementia: mild cognitive impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;561133- 1142
PubMed Link to Article
Lopes-Virella  MFStone  PEllis  SColwell  JA Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977;23882- 884
PubMed
Friedewald  WTLevy  RIFredrickson  DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18499- 502
PubMed
Hixson  JEVernier  DT Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31545- 548
PubMed
Mayeux  ROttman  RMaestre  G  et al.  Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45555- 557
PubMed Link to Article
Fleiss  JL Statistical Methods for Rates and Proportions. 2nd ed. New York: Joseph Wiley & Sons; 1981
Cox  DROakes  D Analysis of Survival Data.  London, England: Chapman & Hall; 1984
Kahn  HASempos  CT Statistical Methods in Epidemiology.  Oxford, England: Oxford University press; 1989
Luis  CALoewenstein  DAAcevedo  ABarker  WWDuara  R Mild cognitive impairment: directions for future research. Neurology 2003;61438- 444
PubMed Link to Article
Curb  JDRodriguez  BLAbbott  RD  et al.  Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999;52971- 975
PubMed Link to Article
Tatemichi  TKDesmond  DWPaik  M  et al.  Clinical determinants of dementia related to stroke. Ann Neurol 1993;33568- 575
PubMed Link to Article
Vermeer  SEPrins  NDden Heijer  THofman  AKoudstaal  PJBreteler  MM Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;3481215- 1222
PubMed Link to Article
Honig  LSKukull  WMayeux  R Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005;64494- 500
PubMed Link to Article
Honig  LSTang  MXAlbert  S  et al.  Stroke and the risk of Alzheimer disease. Arch Neurol 2003;601707- 1712
PubMed Link to Article
Reaven  GMLaws  A Insulin Resistance: The Metabolic Syndrome X.  Totowa, NJ: Humana Press; 1999
Sasaki  NFukatsu  RTsuzuki  K  et al.  Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 1998;1531149- 1155
PubMed Link to Article
Markesbery  WR Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23134- 147
PubMed Link to Article
Tang  MXCross  PAndrews  H  et al.  Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;5649- 56
PubMed Link to Article
Scarmeas  NStern  Y Cognitive reserve and lifestyle. J Clin Exp Neuropsychol 2003;25625- 633
PubMed Link to Article
Harris  MIFlegal  KMCowie  CC  et al.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21518- 524
PubMed Link to Article
Centers for Disease Control and Prevention, Trends in the prevalence and incidence of self-reported diabetes mellitus–United States, 1980-1994. MMWR Morb Mortal Wkly Rep 1997;461014- 1018
PubMed

Figures

Tables

Table Graphic Jump LocationTable 1. Demographic and Other Relevant Characteristics of Persons With and Without Diabetes: The Washington Heights–Inwood Columbia Aging Project, 1992-2003*
Table Graphic Jump LocationTable 2. Relevant Characteristics Among Persons Without and With MCI, Amnestic MCI, and Nonamnestic MCI: The Washington Heights–Inwood Columbia Aging Project, 1992-2003*
Table Graphic Jump LocationTable 3. HRs and 95% CIs Relating Diabetes to MCI, Amnestic MCI, and Nonamnestic MCI*

References

Peila  RRodriguez  BLLauner  LJ Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002;511256- 1262
PubMed Link to Article
Luchsinger  JATang  MXStern  YShea  SMayeux  R Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154635- 641
PubMed Link to Article
Ott  AStolk  RPvan Harskamp  FPols  HAHofman  ABreteler  MM Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999;531937- 1942
PubMed Link to Article
Ott  AStolk  RPHofman  Avan Harskamp  FGrobbee  DEBreteler  MM Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996;391392- 1397
PubMed Link to Article
Leibson  CLRocca  WAHanson  VA  et al.  Risk of dementia among persons with diabetes mellitus: a population- based cohort study. Am J Epidemiol 1997;145301- 308
PubMed Link to Article
Luchsinger  JATang  MXShea  SMayeux  R Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;631187- 1192
PubMed Link to Article
Farris  WMansourian  SChang  Y  et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003;1004162- 4167
PubMed Link to Article
Qiu  WQWalsh  DMYe  Z  et al.  Insulin-degrading enzyme regulates extracellular levels of amyloid beta- protein by degradation. J Biol Chem 1998;27332730- 32738
PubMed Link to Article
Selkoe  DJ The origins of Alzheimer disease: a is for amyloid. JAMA 2000;2831615- 1617
PubMed Link to Article
Smith  MASayre  LMPerry  G Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link. Diabetologia 1996;39247
PubMed Link to Article
Harris  MI Diabetes in America: epidemiology and scope of the problem. Diabetes Care 1998;21(suppl 3)C11- C14
PubMed
Luchsinger  JA Diabetes. In: Aguirre-Molina  M, Molina  CW, Zambrana  RE, eds.Health Issues in the Latino Community. San Francisco, Calif: Jossey-Bass; 2001:277-300
Luchsinger  JAReitz  CHonig  LSTang  MXShea  SMayeux  R Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005;65545- 551
PubMed Link to Article
Petersen  RC Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologia 1995;1326- 344
Petersen  RC Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256183- 194
PubMed Link to Article
Petersen  RCDoody  RKurz  A  et al.  Current concepts in mild cognitive impairment. Arch Neurol 2001;581985- 1992
PubMed Link to Article
Luchsinger  JAMayeux  R Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004;6261- 266
PubMed Link to Article
Tang  MXStern  YMarder  K  et al.  The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279751- 755
PubMed Link to Article
Stern  YAndrews  HPittman  J  et al.  Diagnosis of dementia in a heterogeneous population: development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49453- 460
PubMed Link to Article
Buschke  HFuld  PA Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974;241019- 1025
PubMed Link to Article
Benton  AL The Benton Visual Retention Test.  New York, NY: Psychological Corp; 1955
Folstein  MFFolstein  SEMcHugh  PR “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12189- 198
PubMed Link to Article
Weschler  D Wechsler Memory Scale-Revised Manual.  New York, NY: Psychological Corp; 1987
Mattis  S Mental Status Examination for Organic Mental Syndrome in the Elderly Patient.  New York, NY: Grune & Stratton; 1976
Kaplan  EGoodglass  HWeintraub  S Boston Naming Test.  Philadelphia, Pa: Lea & Febiger; 1983
Benton  ALHamsher  KD Multilingual Aphasia Examination.  Iowa City: University of Iowa; 1976
Goodglass  HKaplan  E Assessment of Aphasia and Related Disorders.  Philadelphia, Pa: Lea & Febiger; 1983
Goodglass  HKaplan  E The Assessment of Aphasia and Related Disorders.  Philadelphia, Pa: Lea & Febiger; 1972
Rosen  W The Rosen Drawing Test.  Bronx, NY: Veterans Administration Medical Center; 1981
Manly  JJBell-McGinty  STang  M-XSchupf  NStern  YMayeux  R Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol 2005;621739- 1746
PubMed Link to Article
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994
Hughes  CPBerg  LDanziger  WLCoben  LAMartin  RL A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140566- 572
PubMed Link to Article
McKhann  GDrachman  DFolstein  MKatzman  RPrice  DStadlan  EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34939- 944
PubMed Link to Article
Petersen  RCStevens  JCGanguli  MTangalos  EGCummings  JLDeKosky  ST Early detection of dementia: mild cognitive impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;561133- 1142
PubMed Link to Article
Lopes-Virella  MFStone  PEllis  SColwell  JA Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977;23882- 884
PubMed
Friedewald  WTLevy  RIFredrickson  DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18499- 502
PubMed
Hixson  JEVernier  DT Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31545- 548
PubMed
Mayeux  ROttman  RMaestre  G  et al.  Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45555- 557
PubMed Link to Article
Fleiss  JL Statistical Methods for Rates and Proportions. 2nd ed. New York: Joseph Wiley & Sons; 1981
Cox  DROakes  D Analysis of Survival Data.  London, England: Chapman & Hall; 1984
Kahn  HASempos  CT Statistical Methods in Epidemiology.  Oxford, England: Oxford University press; 1989
Luis  CALoewenstein  DAAcevedo  ABarker  WWDuara  R Mild cognitive impairment: directions for future research. Neurology 2003;61438- 444
PubMed Link to Article
Curb  JDRodriguez  BLAbbott  RD  et al.  Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999;52971- 975
PubMed Link to Article
Tatemichi  TKDesmond  DWPaik  M  et al.  Clinical determinants of dementia related to stroke. Ann Neurol 1993;33568- 575
PubMed Link to Article
Vermeer  SEPrins  NDden Heijer  THofman  AKoudstaal  PJBreteler  MM Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;3481215- 1222
PubMed Link to Article
Honig  LSKukull  WMayeux  R Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005;64494- 500
PubMed Link to Article
Honig  LSTang  MXAlbert  S  et al.  Stroke and the risk of Alzheimer disease. Arch Neurol 2003;601707- 1712
PubMed Link to Article
Reaven  GMLaws  A Insulin Resistance: The Metabolic Syndrome X.  Totowa, NJ: Humana Press; 1999
Sasaki  NFukatsu  RTsuzuki  K  et al.  Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 1998;1531149- 1155
PubMed Link to Article
Markesbery  WR Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23134- 147
PubMed Link to Article
Tang  MXCross  PAndrews  H  et al.  Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;5649- 56
PubMed Link to Article
Scarmeas  NStern  Y Cognitive reserve and lifestyle. J Clin Exp Neuropsychol 2003;25625- 633
PubMed Link to Article
Harris  MIFlegal  KMCowie  CC  et al.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21518- 524
PubMed Link to Article
Centers for Disease Control and Prevention, Trends in the prevalence and incidence of self-reported diabetes mellitus–United States, 1980-1994. MMWR Morb Mortal Wkly Rep 1997;461014- 1018
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 163

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com